+ Translate

Trh potently reverses epinephrine stimulated hyperglycemia in mice

, : Trh potently reverses epinephrine stimulated hyperglycemia in mice. Brain Research 435(1-2): 112-122

Intracerebroventricular microinjection of thyrotropin-releasing hormone (TRH) potently blocked the development of, as well as promptly reversed, epinephrine-stimulated hyperglycemia in mice. The central antihyperglycemic effect was dose-related (0.1-10 .mu.g), could be reproduced by an intravenous injection of a large dose of the peptide (100 .mu.g), was independent of experimental factors such as stress and age, was effective against other hyperglycemic stimuli, and appeared to be unique to TRH, as it could not be mimicked by many other centrally active peptides known to influence glucoregulation in normoglycemic animals. Moreover, the antihyperglycemic effect of TRH appeared to depend on the structural integrity of the peptide molecule but seemed to be unrelated to the peptide's hypophysiotropic actions or to interaction of the peptide with previously characterized TRH receptors, as it could be mimicked by various analogs devoid of thyrotropin- and prolactin-releasing influences or by peptides resembling TRH in amino acid composition but lacking substantial binding affinity to TRH receptors. Furthermore, the effect of TRH to reverse epinephrine-stimulated hyperglycemia appeared to be mediated by combined action of peripheral sympathetic and parasympathetic mechanisms to stimulate insulin release from the pancreas, since only complete blockade of the central autonomic outflow, but not selective perturbation of the sympathetic or parasympathetic outflow, or depletion of pancreatic insulin could substantially attenuate the antihyperglycemic action. Taken together, these results suggest a new physiologic role of TRH as a central glucoregulatory neuropeptide involved in autonomic modulation of insulin secretion and prevention of hyperglycemia.

(PDF 0-2 workdays service)

Accession: 006839776

Submit PDF Full Text: Here

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Amir, S.; Harel, M.; Rivkind, A.I., 1987: Thyrotropin-releasing hormone potently reverses epinephrine-stimulated hyperglycemia in mice. Intracerebroventricular microinjection of thyrotropin-releasing hormone (TRH) potently blocked the development of, as well as promptly reversed, epinephrine-stimulated hyperglycemia in mice. The central antihyperglycemic effect was dose-related (0...

Amir S.; Harel M.; Rivkind A.I., 1986: Trh potently antagonizes catecholamine induced hyperglycemia in mice. Society for Neuroscience Abstracts 12(1): 219

Chen, L.; McNulty, J.; Anderson, D.; Liu, Y.; Nystrom, C.; Bullard, S.; Collins, J.; Handlon, A.L.; Klein, R.; Grimes, A.; Murray, D.; Brown, R.; Krull, D.; Benson, B.; Kleymenova, E.; Remlinger, K.; Young, A.; Yao, X., 2010: Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. Bile acid sequestrants (BAS) have shown antidiabetic effects in both humans and animals but the underlying mechanism is not clear. In the present study, we evaluated cholestyramine in Zucker diabetic fatty (ZDF) rats. Although control ZDF rats had...

Park, S.Hyun.; Lee, S.Gil.; Kang, S.Keel.; Chung, S.Hyun., 2006: Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice. Non-alcoholic fatty liver disease (NAFLD) is common in obesity. However, weight reduction alone does not prevent the progression of NAFLD to end-stage disease associated with the development of cirrhosis and liver disease: In a previous experiment...

Butler, M.; McKay, R.A.; Popoff, I.J.; Gaarde, W.A.; Witchell, D.; Murray, S.F.; Dean, N.M.; Bhanot, S.; Monia, B.P., 2002: Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is crucial for metabolic responses to insulin, and defects in PI3K signaling have been demonstrated in type 2 diabetes. PTEN (MMAC1) is a lipid/protein phosphatase that can n...

Xue, S.; Posgai, A.; Wasserfall, C.; Myhr, C.; Campbell-Thompson, M.; Mathews, C.E.; Brusko, T.; Rabinovitch, A.; Savinov, A.; Battaglia, M.; Schatz, D.; Haller, M.; Atkinson, M.A., 2016: Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes. An increasing number of therapies have proven effective at reversing hyperglycemia in the nonobese diabetic (NOD) mouse model of type 1 diabetes (T1D), yet situations of successful translation to human T1D are limited. This may be partly due to ev...

Yen, T.T.; Gill, A.M.; Powell, J.G.; Sampson, B.M., 1992: Ciglitazone prevents and reverses dexamethasone-induced hyperglycemia in female viable yellow mice. Hypercorticism has been observed in numerous obese and diabetic animal models. Adrenalectomy reduces adiposity, hyperglycemia, hyperinsulinemia, and insulin resistance in these animals. The effects of adrenalectomy can be reversed by glucocorticoi...

Yuan, M.; Cai, D.; Lee, J.; Hansen, L.; Li, Z.W.i; Karin, M.; Fisher, S.; Shoelson, S., 2001: Heterozygous knock-out of IKKbeta reverses insulin resistance, hyperglycemia and dyslipidemia in obese mice. Diabetes 50(Supplement 2): A57-A58, June

Takeuchi N.; Yamada J.; Sugimoto Y.; Kimura I.; Horisaka K., 1989: Antagonistic effects of serotonin on epinephrine induced hyperglycemia in mice. Japanese Journal of Pharmacology 49(SUPPL): 184P

Fishel, C.W.; Szentivanyi, A., 1962: The absence of epinephrine-induced hyperglycemia inpertussis-sensitized mice. Fed Proc 21(2): 271